SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

SEC Comment Letter 0000000000-23-008736 to Cannaisseur Group Inc. (CIK 0001879270) (TCRG)

Cannaisseur Group Inc. (CIK 0001879270)
Date: Aug. 10, 2023 · CIK: 0001879270 · Accession: 0000000000-23-008736

AI Filing Summary & Sentiment

File numbers found in text: 333-262710

Referenced dates: March 18, 2022

Date
August 10, 2023
Author
Not clearly detected
Form
UPLOAD
Company
Cannaisseur Group Inc. (CIK 0001879270)

Letter

United States securities and exchange commission logo August 10, 2023 Floretta Gogo Chief Executive Officer The Cannaisseur Group Inc. 1039 Grant St Se Ste B24 Atlanta, GA 30315 Re:The Cannaisseur Group Inc. Amendment No. 3 to Registration Statement on Form S-1 Filed July 18, 2023 File No. 333-262710 Dear Floretta Gogo: We have reviewed your amended registration statement and have the following comments. In some of our comments, we may ask you to provide us with information so we may better understand your disclosure. Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe our comments apply to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response. After reviewing any amendment to your registration statement and the information you provide in response to these comments, we may have additional comments. Unless we note otherwise, our references to prior comments are to comments in our October 3, 2022 letter. Amendment No. 3 to Registration Statement on Form S-1 Cover Page 1.We refer to prior comment 1. Please revise the prospectus cover page (as opposed to the registration statement cover page) to clearly state the offering price of the shares to be offered by you and the offering price of the shares to be offered by the Selling Shareholders. 2.We note your response to prior comment 1 and your revised disclosure indicating that the Selling Shareholders may offer shares of common stock "from time to time through public or private transactions at prevailing market prices or privately-negotiated prices." We further note your disclosure that your shares will not be listed on any exchange before the offering is consummated. Accordingly, the price at which the shares will be offered must

FirstName LastNameFloretta Gogo Comapany NameThe Cannaisseur Group Inc. August 10, 2023 Page 2 FirstName LastName Floretta Gogo The Cannaisseur Group Inc. August 10, 2023 Page 2 be fixed until a market develops. Please revise your disclosure accordingly. Prospectus Summary Corporate History, page 4 3.We note your response to prior comment 5 and note that you have filed the Atlanda CBD Operating Agreement. However, neither this agreement nor any of the others that have been filed appear to provide the governing terms of the Atlanta CBD preferred stock. Therefore, we re-issue comment 5. Please file the certificate of incorporation or other equivalent document of Atlanta CBD Inc. that contains the terms of the preferred stock. Please also revise your disclosure on page 4 to reflect your statements to us that the preferred stock is not convertible into common stock of your Company and that profit distributions have not been paid to preferred shareholders. Please clarify if there is any cap on profit distributions that could be paid to preferred shareholders.

Please also revise here, on page 6 and in the Use of Proceeds section to disclose that proceeds from the offering could be used to pay redemption amounts of up to $37,875 if the holders of preferred stock redeem their shares. Use of Proceeds, page 18 4.We note your disclosure on page 18 that you plan to use the funds raised in this offering to purchase assets to grow your business and that if you do not receive sufficient funds in the offering, you will have to rely on other sources of funds to grow your business. This disclosure inconsistent with the disclosure in the Use of Proceeds table on page 19 indicating that the proceeds will be used for operational costs, marketing, product development and new hires. We further note your disclosure on page 26 that the funds from the offering and other sources, if necessary, will be used to acquire additional assets to support and grow Atlanta CBD's operations.

Please revise your disclosure here and throughout to clarify whether the funds from the offering will be used to purchase assets you will use to grow your business, develop and market your own products or make further investments in Atlanta CBD's business. To the extent the funds will be used to grow Atlanta CBD's business, rather than your business, please revise prominently through the prospectus to disclose this fact and include appropriate risk factor disclosure. If you anticipate transferring funds raised in this offering to Atlanta CBD, please also revise your disclosure accordingly. Management's Discussion and Analysis of Financial Conditions and Plan of Operation Liquidity and Capital Resources, page 23 5.We note your statement on page 24 that you have succeeded in securing investments of up to $20,000. Please revise to describe the material terms of these investments.

FirstName LastNameFloretta Gogo Comapany NameThe Cannaisseur Group Inc. August 10, 2023 Page 3 FirstName LastName Floretta Gogo The Cannaisseur Group Inc. August 10, 2023 Page 3 Description of Business, page 26 6.We refer to prior comment 9. We further note that you continue to use "the Company", "we" and "our" to refer to Atlanta CBD. For example:

•On pages 4 and 26, "Our mission is to grow one of the best hemp plants and produce high-quality infused products to provide customers with products and services they trust." •On pages 4 and 28, "we do not ship such products to those states, and we disclose this and warn consumers of the restrictions on the INNO Medicinals website." •On page 25, "The Company periodically reviews the value of items in inventory and provides write-downs or write-offs of inventory based on its assessment of market conditions." •On page 25, "The Company sells CBD related products in a retail location in Atlanta, Georgia and through e-commerce." •On page 25, "The Company sells products at their one retail location and via web site sales." •On page 26, "We do not believe that our hemp-derived CBD products..." •On page 27, "All the full Spectrum Hemp CBD Infused products the Company sells..." •On page 28, "Our Name, our reputation, and our unique branded products promote a positive shopping experience for customers." as well as the sentence at the end of this paragraph.

Please revise further to clearly distinguish between your operations and Atlanta CBD's operations. 7.Your disclosure on page 24 states that you are working with a manufacturer to develop a time-release product which you believe is unique to the market and has potential to generate substantial revenue. Please revise your Business section to describe the material terms of this arrangement. Selling Shares, page 37 8.We note your response to comment 17. Despite your response, the Selling Shares section has not been revised to provide the information required by Item 507 of Regulation S-K. Please update the section to provide all required information, including the nature of any position, office, or other material relationship the selling shareholder has had within the past three years and clarify the amount of securities held by the security holder prior to the offering, the amount offered by each security holder and the amount and percentage of the class to be held by each security holder after completion of the offering.

FirstName LastNameFloretta Gogo Comapany NameThe Cannaisseur Group Inc. August 10, 2023 Page 4 FirstName LastName Floretta Gogo The Cannaisseur Group Inc. August 10, 2023 Page 4 General 9.Please file Exhibit 107 to include filing fees and associated information. Refer to SEC Release No. 33-10997 for additional guidance. 10.We note your response to comment 7 of our letter dated March 18, 2022. Please provide a detailed legal analysis regarding whether The Cannaisseur Group, Inc. (the “Company”) and its subsidiaries meet the definition of an “investment company” under Section 3(a)(1)(C) of the Investment Company Act of 1940 (“Investment Company Act”). In your response, please include all relevant calculations under Section 3(a)(1)(C), identifying each constituent part of the numerators and denominators. In your response, please also describe and discuss: •your proposed treatment of the Company’s interest in Atlanta CBD Inc. (“Atlanta CBD”); •whether and how Atlanta CBD meets the definition of a “majority-owned subsidiary” as defined in section 2(a)(24) of the Investment Company Act, including whether the Company owns 50% or more of the “voting securities” of the Company, as that term is defined in section 2(a)(42) of the Investment Company Act; •whether preferred stock issued by Atlanta CBD are “voting securities” as defined in section 2(a)(42) of the Investment Company Act; •whether the minority shareholders of Atlanta CBD are able to, in practice, control Atlanta CBD and appoint the majority of the members of its board of directors by virtue of these shareholders’ interests in the Company; and •any other substantive determinations and/or characterizations of assets that are material to your calculations. 11.Please provide a detailed legal analysis regarding whether the Company and its subsidiaries meet the definition of an “investment company” under Section 3(a)(1)(A) of the Investment Company Act. In your response, please address, in detail, each of the factors outlined in Tonapah Mining Company of Nevada, 26 SEC 426 (1947) and provide legal and factual support for your analysis of each such factor. 12.Please revise your registration statement to provide the information required by Items 13, 14 and 15 of Form S-1.

FirstName LastNameFloretta Gogo Comapany NameThe Cannaisseur Group Inc. August 10, 2023 Page 5 FirstName LastName Floretta Gogo The Cannaisseur Group Inc. August 10, 2023 Page 5 You may contact Gary Newberry at 202-551-3761 or Lynn Dicker at 202-551-3616 if you have questions regarding comments on the financial statements and related matters. Please contact Alan Campbell at 202-551-4224 or Suzanne Hayes at 202-551-3675 with any other questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Elton F. Norman, Esquire

Show Raw Text
United States securities and exchange commission logo
August 10, 2023
Floretta Gogo
Chief Executive Officer
The Cannaisseur Group Inc.
1039 Grant St Se Ste B24
Atlanta, GA 30315
Re:The Cannaisseur Group Inc.
Amendment No. 3 to Registration Statement on Form S-1
Filed July 18, 2023
File No. 333-262710
Dear Floretta Gogo:
            We have reviewed your amended registration statement and have the following
comments.  In some of our comments, we may ask you to provide us with information so we
may better understand your disclosure.
            Please respond to this letter by amending your registration statement and providing the
requested information.  If you do not believe our comments apply to your facts and
circumstances or do not believe an amendment is appropriate, please tell us why in your
response.
            After reviewing any amendment to your registration statement and the information you
provide in response to these comments, we may have additional comments.  Unless we note
otherwise, our references to prior comments are to comments in our October 3, 2022 letter.
Amendment No. 3 to Registration Statement on Form S-1
Cover Page
1.We refer to prior comment 1. Please revise the prospectus cover page (as opposed to the
registration statement cover page) to clearly state the offering price of the shares to be
offered by you and the offering price of the shares to be offered by the Selling
Shareholders.
2.We note your response to prior comment 1 and your revised disclosure indicating that the
Selling Shareholders may offer shares of common stock "from time to time through public
or private transactions at prevailing market prices or privately-negotiated prices." We
further note your disclosure that your shares will not be listed on any exchange before the
offering is consummated. Accordingly, the price at which the shares will be offered must

 FirstName LastNameFloretta Gogo
 Comapany NameThe Cannaisseur Group Inc.
 August 10, 2023 Page 2
 FirstName LastName
Floretta Gogo
The Cannaisseur Group Inc.
August 10, 2023
Page 2
be fixed until a market develops. Please revise your disclosure accordingly.
Prospectus Summary
Corporate History, page 4
3.We note your response to prior comment 5 and note that you have filed the Atlanda CBD
Operating Agreement. However, neither this agreement nor any of the others that have
been filed appear to provide the governing terms of the Atlanta CBD preferred stock.
Therefore, we re-issue comment 5. Please file the certificate of incorporation or other
equivalent document of Atlanta CBD Inc. that contains the terms of the preferred stock.
Please also revise your disclosure on page 4 to reflect your statements to us that the
preferred stock is not convertible into common stock of your Company and that profit
distributions have not been paid to preferred shareholders. Please clarify if there is any cap
on profit distributions that could be paid to preferred shareholders.

Please also revise here, on page 6 and in the Use of Proceeds section to disclose that
proceeds from the offering could be used to pay redemption amounts of up to $37,875 if
the holders of preferred stock redeem their shares.
Use of Proceeds, page 18
4.We note your disclosure on page 18 that you plan to use the funds raised in this offering to
purchase assets to grow your business and that if you do not receive sufficient funds in the
offering, you will have to rely on other sources of funds to grow your business. This
disclosure inconsistent with the disclosure in the Use of Proceeds table on page 19
indicating that the proceeds will be used for operational costs, marketing, product
development and new hires. We further note your disclosure on page 26 that the funds
from the offering and other sources, if necessary, will be used to acquire additional assets
to support and grow Atlanta CBD's operations.

Please revise your disclosure here and throughout to clarify whether the funds from the
offering will be used to purchase assets you will use to grow your business, develop and
market your own products or make further investments in Atlanta CBD's business. To the
extent the funds will be used to grow Atlanta CBD's business, rather than your business,
please revise prominently through the prospectus to disclose this fact and include
appropriate risk factor disclosure. If you anticipate transferring funds raised in this
offering to Atlanta CBD, please also revise your disclosure accordingly.
Management's Discussion and Analysis of Financial Conditions and Plan of Operation
Liquidity and Capital Resources, page 23
5.We note your statement on page 24 that you have succeeded in securing investments of up
to $20,000. Please revise to describe the material terms of these investments.

 FirstName LastNameFloretta Gogo
 Comapany NameThe Cannaisseur Group Inc.
 August 10, 2023 Page 3
 FirstName LastName
Floretta Gogo
The Cannaisseur Group Inc.
August 10, 2023
Page 3
Description of Business, page 26
6.We refer to prior comment 9. We further note that you continue to use "the Company",
"we" and "our" to refer to Atlanta CBD. For example:

•On pages 4 and 26, "Our mission is to grow one of the best hemp plants and produce
high-quality infused products to provide customers with products and services they
trust."
•On pages 4 and 28, "we do not ship such products to those states, and we disclose this
and warn consumers of the restrictions on the INNO Medicinals website."
•On page 25, "The Company periodically reviews the value of items in inventory and
provides write-downs or write-offs of inventory based on its assessment of market
conditions."
•On page 25, "The Company sells CBD related products in a retail location in Atlanta,
Georgia and through e-commerce."
•On page 25, "The Company sells products at their one retail location and via web site
sales."
•On page 26, "We do not believe that our hemp-derived CBD products..."
•On page 27, "All the full Spectrum Hemp CBD Infused products the Company
sells..."
•On page 28, "Our Name, our reputation, and our unique branded products promote a
positive shopping experience for customers." as well as the sentence at the end of this
paragraph.

Please revise further to clearly distinguish between your operations and Atlanta CBD's
operations.
7.Your disclosure on page 24 states that you are working with a manufacturer to develop a
time-release product which you believe is unique to the market and has potential to
generate substantial revenue. Please revise your Business section to describe the material
terms of this arrangement.
Selling Shares, page 37
8.We note your response to comment 17. Despite your response, the Selling Shares section
has not been revised to provide the information required by Item 507 of Regulation S-K.
Please update the section to provide all required information, including the nature of any
position, office, or other material relationship the selling shareholder has had within the
past three years and clarify the amount of securities held by the security holder prior to the
offering, the amount offered by each security holder and the amount and percentage of the
class to be held by each security holder after completion of the offering.

 FirstName LastNameFloretta Gogo
 Comapany NameThe Cannaisseur Group Inc.
 August 10, 2023 Page 4
 FirstName LastName
Floretta Gogo
The Cannaisseur Group Inc.
August 10, 2023
Page 4
General
9.Please file Exhibit 107 to include filing fees and associated information. Refer to SEC
Release No. 33-10997 for additional guidance.
10.We note your response to comment 7 of our letter dated March 18, 2022. Please provide a
detailed legal analysis regarding whether The Cannaisseur Group, Inc. (the “Company”)
and its subsidiaries meet the definition of an “investment company” under Section
3(a)(1)(C) of the Investment Company Act of 1940 (“Investment Company Act”). In your
response, please include all relevant calculations under Section 3(a)(1)(C), identifying
each constituent part of the numerators and denominators. In your response, please also
describe and discuss:
•your proposed treatment of the Company’s interest in Atlanta CBD Inc. (“Atlanta
CBD”);
•whether and how Atlanta CBD meets the definition of a “majority-owned subsidiary”
as defined in section 2(a)(24) of the Investment Company Act, including whether the
Company owns 50% or more of the “voting securities” of the Company, as that term
is defined in section 2(a)(42) of the Investment Company Act;
•whether preferred stock issued by Atlanta CBD are “voting securities” as defined in
section 2(a)(42) of the Investment Company Act;
•whether the minority shareholders of Atlanta CBD are able to, in practice, control
Atlanta CBD and appoint the majority of the members of its board of directors by
virtue of these shareholders’ interests in the Company; and
•any other substantive determinations and/or characterizations of assets that are
material to your calculations.
11.Please provide a detailed legal analysis regarding whether the Company and its
subsidiaries meet the definition of an “investment company” under Section 3(a)(1)(A) of
the Investment Company Act. In your response, please address, in detail, each of the
factors outlined in Tonapah Mining Company of Nevada, 26 SEC 426 (1947) and provide
legal and factual support for your analysis of each such factor.
12.Please revise your registration statement to provide the information required by Items 13,
14 and 15 of Form S-1.

 FirstName LastNameFloretta Gogo
 Comapany NameThe Cannaisseur Group Inc.
 August 10, 2023 Page 5
 FirstName LastName
Floretta Gogo
The Cannaisseur Group Inc.
August 10, 2023
Page 5
            You may contact Gary Newberry at 202-551-3761 or Lynn Dicker at 202-551-3616 if
you have questions regarding comments on the financial statements and related matters.  Please
contact Alan Campbell at 202-551-4224 or Suzanne Hayes at 202-551-3675 with any other
questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Elton F. Norman, Esquire